Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Insider Nur Nicholson Sells 3,948 Shares

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Nur Nicholson sold 3,948 shares of the firm’s stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $30.43, for a total value of $120,137.64. Following the completion of the transaction, the insider now directly owns 84,489 shares of the company’s stock, valued at $2,571,000.27. The trade was a 4.46 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Nur Nicholson also recently made the following trade(s):

• On Friday, January 17th, Nur Nicholson sold 2,145 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $29.96, for a total transaction of $64,264.20.

Apellis Pharmaceuticals Trading Up 1.2 %

Apellis Pharmaceuticals stock opened at $30.76 on Friday. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36. Apellis Pharmaceuticals, Inc. has a 1 year low of $24.34 and a 1 year high of $71.90. The firm’s 50-day moving average is $31.95 and its 200-day moving average is $33.25. The company has a market cap of $3.83 billion, a P/E ratio of -15.15 and a beta of 0.94.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its earnings results on Tuesday, November 5th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.14). The company had revenue of $196.83 million for the quarter, compared to the consensus estimate of $200.00 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The firm’s revenue for the quarter was up 78.3% compared to the same quarter last year. During the same period last year, the company posted ($1.17) earnings per share. On average, equities analysts expect that Apellis Pharmaceuticals, Inc. will post -1.71 earnings per share for the current year.

Institutional Investors Weigh In On Apellis Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in APLS. KBC Group NV grew its position in shares of Apellis Pharmaceuticals by 3,862.3% during the fourth quarter. KBC Group NV now owns 104,287 shares of the company’s stock worth $3,328,000 after acquiring an additional 101,655 shares during the last quarter. Merit Financial Group LLC bought a new position in Apellis Pharmaceuticals in the 4th quarter worth about $254,000. Hennion & Walsh Asset Management Inc. increased its stake in shares of Apellis Pharmaceuticals by 135.6% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 29,740 shares of the company’s stock valued at $949,000 after purchasing an additional 17,115 shares during the period. Eastern Bank boosted its position in shares of Apellis Pharmaceuticals by 87.0% during the fourth quarter. Eastern Bank now owns 21,500 shares of the company’s stock worth $686,000 after buying an additional 10,000 shares during the period. Finally, JPMorgan Chase & Co. grew its holdings in Apellis Pharmaceuticals by 23.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company’s stock worth $112,036,000 after buying an additional 735,160 shares in the last quarter. 96.29% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Piper Sandler lowered their target price on Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating on the stock in a report on Wednesday, November 6th. Robert W. Baird dropped their price objective on Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. Needham & Company LLC reduced their target price on shares of Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. William Blair assumed coverage on shares of Apellis Pharmaceuticals in a research note on Wednesday, October 16th. They set an “outperform” rating on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $57.00 price objective on shares of Apellis Pharmaceuticals in a research report on Tuesday, January 14th. Eight analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $46.71.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).